Indications up for PET
Wednesday, 16 July, 2008
The Australian Government has expanded approved indications for Medicare reimbursement for PET imaging.
The inclusion of ovarian cancer, colorectal cancer and recurrent melanoma brings to a total of six the number of PET indications which are approved for reimbursement through Medicare.
One company poised to take advantage of this decision is Cyclopharm [ASX: CYC], which has already commenced development of two PET radiopharmacy sites.
The first is to be built at the Macquarie University Private Hospital, and should be completed in the first half of next year.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
